Evaluation of the whole-blood alere q nat point-of-care RNA assay for HIV-1 viral load monitoring in a primary health care setting in Mozambique

Journal of Clinical Microbiology

Volumn 54, Issue 8, 2016, Pages 2104-2108

  Jani, Ilesh V ^a   Meggi, Bindiya ^a   Vubil, Adolfo ^a   Sitoe, Nádia E ^a   Bhatt, Nilesh ^a   Tobaiwa, Ocean ^b   Quevedo, Jorge I ^b   Loquiha, Osvaldo ^c   Lehe, Jonathan D ^b   Vojnov, Lara ^b   Peter, Trevor F ^b  

^a Institut Nacional da Saude   (Mozambique)

^b CLINTON HEALTH ACCESS INITIATIVE   (United States)

^c EDUARDO MONDLANE UNIVERSITY   (Mozambique)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC KIT; DRUG MONITORING; DRUG TREATMENT FAILURE; FEASIBILITY STUDY; FEMALE; HEALTH CARE FACILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; MEASUREMENT PRECISION; MOZAMBIQUE; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; VIRUS LOAD; BLOOD; CHILD; COMPARATIVE STUDY; EVALUATION STUDY; GERMANY; HIV INFECTIONS; MIDDLE AGED; POINT OF CARE SYSTEM; PROCEDURES; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CROSS-SECTIONAL STUDIES; DRUG MONITORING; FEMALE; GERMANY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MOZAMBIQUE; POINT-OF-CARE SYSTEMS; PRIMARY HEALTH CARE; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; YOUNG ADULT;

EID: 84979609984     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00362-16     Document Type: Article

References (22)

1. World Health Organization. 2015. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization, Geneva, Switzerland.
2. UNAIDS. 2014. 90-90-90. An ambitious treatment target to help end the AIDS epidemic. UNAIDS, Washington, D.C.
3. UNAIDS. 2014. Landmark HIV diagnostic access program will save 150m and help achieve new global goals on HIV. UNAIDS, Washington, D.C.
4. UNITAID. 2015. HIV/AIDS diagnostic technology landscape, 5th ed. UNITAID, Vernier, Switzerland.
5. Parkin NT. 2014. Measurement of HIV-1 viral load for drug resistance surveillance using dried blood spots: literature review and modeling of contribution of DNA and RNA. AIDS Rev 16:160-171.
6. Alere Inc. 2016. Alere q HIV-1/2 Detect. How the assay works. http://www . alerehiv. com/ww/home/hiv-screening/alere-q-hiv-1-2-detect/detect . html. Alere Inc., Waltham, M.A.
7. Ullrich T, Ermantraut E, Schulz T, Steinmetzer K. 2012. Competitive reporter monitored amplification (CMA)-quantification of molecular targets by real time monitoring of competitive reporter hybridization. PLoS One 7:e35438. http://dx. doi. org/10. 1371/journal. pone. 0035438.
8. Jani IV, Meggi B, Mabunda N, Vubil A, Sitoe NE, Tobaiwa O, Quevedo JI, Lehe JD, Loquiha O, Vojnov L, Peter TF. 2014. Accurate early infant HIV diagnosis in primary health clinics using a point-of-care nucleic acid test. J Acquir Immune Defic Syndr 67:e1-e4. http://dx. doi. org/10. 1097 /QAI. 0000000000000250.
9. Boyer S, Eboko F, Camara M, Abe C, Nguini ME, Koulla-Shiro S, Moatti JP. 2010. Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS 24(Suppl 1):S5-S15. http://dx. doi. org/10. 1097/01. aids . 0000366078. 45451. 46.
10. Bland JM, Altman DG. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 8:307-310.
11. Granade TC. 2005. Use of rapid HIV antibody testing for controlling the HIV pandemic. Expert Rev Anti Infect Ther 3:957-969. http://dx. doi. org /10. 1586/14787210. 3. 6. 957.
12. Pai N, Barick R, Tulsky J, Shivkumar P, Cohan D, Kalantri S, Pai M, Klein M, Chhabra S. 2008. Impact of round-the-clock, rapid oral fluid HIV testing of women in labor in rural India. PLoS Med 5:e92. http://dx . doi. org/10. 1371/journal. pmed. 0050092.
13. Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa, Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, Bonner K, Rousseau C, Garnett G, Cambiano V, Nakagawa F, Ford D, Bansi-Matharu L, Miners A, Lundgren J, Eaton J, Parkes-Ratanshi R, Katz Z, Maman D, Ford N, Vitoria M, Doherty M, Dowdy D, Nichols B, Murtagh M, Wareham M, Palamountain KM, Chakanyuka Musanhu C, Stevens W, Katzenstein D, Ciaranello A, Barnabas R, Braithwaite RS, Bendavid E, Nathoo K, Van De Vijver D, Wilson D, Holmes C, Bershteyn A, Walker S, Raizes E, Jani I, Nelson L, Peeling R, Terris-Prestholt F, Murungu J, Mutasa-Apollo T, Hallett T, Revill P. 2015. Sustainable HIV treatment in Africa through viral-loadinformed differentiated care. Nature 528:S68-S76. http://dx. doi. org/10 . 1038/nature16046.
14. Bonner K, Mezochow A, Roberts T, Ford N, Cohn J. 2013. Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr 64:74-78. http://dx. doi. org/10. 1097/QAI . 0b013e31829f05a.c.
15. Ellman T, Metcalf C, Bygrave H, Munyaradzi D, Kizito W, Garone D, Mtangirwa J, Khabala K, Malenga M. 2013. HIV viral resuppression after adherence counselling: findings from projects in three countries. ICASA, Cape Town, South Africa.
16. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, Wood R. 2007. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (Lond) 12:83-88.
17. Parker LA, Jobanputra K, Azih C. 2013. Use of viral load (VL) monitoring to enable better targeting of adherence support for antiretroviral therapy (ART) compliance in Swaziland. ICASA, Cape Town, South Africa.
18. Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MW, Dabis F, Tuboi S, Sprinz E, Pujades-Rodriguez M, Calmy A, Kumarasamy N, Nash D, Jahn A, MacPhail P, Lüthy R, Wood R, Egger M. 2009. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 23:1867-1874. http://dx. doi. org/10. 1097 /QAD. 0b013e32832e05b2.
19. Jani IV. 2010. The need for systematic evaluations of diagnostic tests. Clin Infect Dis 51:609-610. http://dx. doi. org/10. 1086/655763.
20. European AIDS Clinical Society. 2014. Guidelines version 7. 1. European AIDS Clinical Society, Brussels, Belgium.
21. Hoen B, Bonnet F, Delaugerre C, Delobel P, Goujard C, L'Hénaff M, Persiaux R, Rey D, Rouzioux C, Taburet AM, Morlat P, 2013 French HIV Expert Group. 2014. French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults. J Int AIDS Soc 17:19034. http://dx. doi . org/10. 7448/IAS. 17. 1. 19034.
22. U. S. Department of Health. 2014. Panel on antiretroviral guidelines for adults and adolescents: guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. U. S. Department of Health, Washington, D.C.